中文摘要：

目的 探讨地西他滨治疗骨髓增生异常综合征（myelodysplastic syndromes,MDS）和急性髓系白血病（acute myelocytic leukemia,AML）的临床疗效及不良反应.方法 收集马鞍山市人民医院血液科收治的12例MDS及AML患者,给予地西他滨联合半量HAG方法治疗,观察疗效及不良反应.结果 4例完全缓解,5例部分缓解,总有效率75％（9/12）,平均无疾病进展生存时间为10.33月,3例死亡;8例出现Ⅳ度骨髓抑制,发生率为66.7％（8/12）,6例并发感染,发生率为50％（6/12）.其他不良反应未发现.结论 地西他滨联合半量HAG方案可以有效地治疗MDS及AML,主要不良反应为骨髓抑制及感染.

英文摘要：

Objective To investigate clinical efficacy and side effects for the patients with myelodys-plastic syndromes （MDS） and acute myeloid leukemia （AML） treated by decitabine with half the a-mount of HAG. Methods Twelve cases of MDS and AML patients from department of Hematolgy, Maans-han People＇s Hospital were given decitabine combined with half the amount of HAG and clinical efficacy and side effects were observed. Results Four patients achieved complete remission ,five patients achieved partial remission and the total efficiency rate was 75% （9/12）. The average progression -free survival time was 10.33 months except the death of three patients. Eight patients appeared grade IV myelosup- pression and the rate was 66.7% （8/12）. Six patients had concurrent infection and the rate was 50% （6/12）. Other side effects were not been observed. Conclusion The therapy program of decitabine with half the amount of HAG can effectively treat MDS and AML, but the major side effects were myelosup- pression and infection.